{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-002384","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2023-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.542248+00:00","generated_at":"2026-06-19T19:42:52.168607+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"aTyr Pharma launches $50M public offering of 22.2M shares at $2.25; plans Phase 2 SSc-ILD study","bullets":["Gross proceeds ~$50M from 22,225,000 shares at $2.25; underwriters have 30-day option for 3,333,750 additional shares.","FDA cleared IND for efzofitimod in SSc-ILD; Phase 2 proof-of-concept study planned for 2023.","Phase 2 study: 28-week, randomized, double-blind, placebo-controlled, 2:2:1 dosing 270 mg, 450 mg efzofitimod or placebo; 25 patients.","Orphan drug designations: FDA: sarcoidosis (Jan 2022) and systemic sclerosis (Apr 2022); EU: sarcoidosis (Jan 2023).","Risk factor supplement: no guarantee of orphan drug exclusivity for future indications or jurisdictions."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-002384","json":"https://secwatch.observer/filing/0000950170-23-002384.json","markdown":"https://secwatch.observer/filing/0000950170-23-002384.md","text":"https://secwatch.observer/filing/0000950170-23-002384.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023002384/0000950170-23-002384-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017023002384/life-20230208.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T19:42:52.168607+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}